INDIANAPOLIS, Feb. 19, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months.

Sanofi and Regeneron Pharmaceuticals, Inc. announced that data from two Phase 2 trials with  SAR236553 / REGN727 , an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 ( proprotein convertasesubtilisin / kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.